Canagliflozin
Canagliflozin (SGLT2 Inhibitor for Longevity)
SGLT2 inhibitor FDA-approved for diabetes that has shown lifespan extension in the NIA Interventions Testing Program. Promotes glucose excretion through urine, mimicking caloric restriction. Also provides cardiovascular and kidney protection beyond glucose lowering.
📊 Evidence by Outcome
Extended lifespan (mice)
3 studies • Consistency: Moderate • Effect: Moderate
Cardiovascular protection
3 studies • Consistency: Moderate • Effect: Moderate
Kidney protection
3 studies • Consistency: Moderate • Effect: Moderate
Glycemic control
3 studies • Consistency: Moderate • Effect: Moderate
Caloric restriction mimetic
3 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 2 Citations
NIA ITP: Canagliflozin Lifespan Extension
••2020
Key Finding: Canagliflozin extended median lifespan by ~14% in male mice across 3 independent testing sites
CREDENCE Trial
••2019
Key Finding: Canagliflozin reduced kidney failure risk by 30% and cardiovascular events in diabetic kidney disease patients
Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
$50-300/month
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.